Symbol="TARS"
AssetType="Common Stock"
Name="Tarsus PharmaceuticalsÂ Inc"
Description="Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California."
CIK="1819790"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="15440 LAGUNA CANYON ROAD, IRVINE, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="450838000"
EBITDA="-67755000"
PERatio="None"
PEGRatio="None"
BookValue="7.22"
DividendPerShare="0"
DividendYield="0"
EPS="-1.77"
RevenuePerShareTTM="1.049"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.217"
ReturnOnEquityTTM="-0.405"
RevenueTTM="27777000"
GrossProfitTTM="-17763000"
DilutedEPSTTM="-1.77"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="3.638"
AnalystTargetPrice="49.29"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="24.75"
PriceToBookRatio="2.038"
EVToRevenue="12.78"
EVToEBITDA="-3.446"
Beta="0.695"
num_52WeekHigh="25.25"
num_52WeekLow="11.33"
num_50DayMovingAverage="18.59"
num_200DayMovingAverage="16.07"
SharesOutstanding="26803700"
DividendDate="None"
ExDividendDate="None"
symbol="TARS"
open="16.72"
high="17.26"
low="16.30"
price="16.82"
volume="285006.00"
latest_trading_day="2023-08-11"
previous_close="17.01"
change="-0.19"
change_percent="-1.1170%"
aroon_positive_momentum_days="66"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="66"
Volume_recent_avg="306430"
Change_recent_avg="0.05"
Delta_recent_avg="0.89"
Variance_recent_avg="0.44"
Change_ratio_recent_avg="0.16"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="66"
Aroon_momentum_negative="34"
image_negative_thumbnail_id_1="490"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0115.jpeg"
image_negative_thumbnail_id_2="1089"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0122.jpeg"
image_neutral_thumbnail_id_1="598"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0001.jpeg"
image_neutral_thumbnail_id_2="432"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Neutral_Landscape_0019.jpeg"
image_positive_thumbnail_id_1="976"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0138.jpeg"
image_positive_thumbnail_id_2="964"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0126.jpeg"
image_professor_thumbnail_id_1="1174"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
image_professor_thumbnail_id_2="1185"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0019.jpeg"
